An interventional study of E-liquid Flavor 1 and E-liquid Flavor 2 in Nicotine Addiction, E-Cig Use and Cigarette Smoking, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 21 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Yale University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Tobacco Use Disorder by Yale University — 5 open to participants now, 5 under way, none of them phase 3. Tobacco Use Disorder · Yale University.
Among the 58 studies in Tobacco Use Disorder by Yale University, this one is the 17th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2024, is one of 20 with no phase, and was the 51st registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →5 of the 58 studies in Tobacco Use Disorder by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 21+
Yale University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 21 Years to 44 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 14 · Phase 3 1 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is below the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 41 across the 56 interventional studies, 27 across the 2 observational. Of the 52 that completed or were terminated, 33 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
1 of the studies in Tobacco Use Disorder by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398976Yale UniversitySex Differences in E-Cigarette Perception | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 58 studies in Tobacco Use Disorder by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to examine the influence of sex on sensory effects, appeal, and reinforcing value of nicotine containing e-cigs in popular flavor components; sweet and cooling.
This study looks at the effect of sex on the sensory effects of flavor components in e-cigarettes. Regular combustible tobacco users will sample 3 different flavored e-cigarettes containing nicotine in a human lab paradigm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3
All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3
All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
Other: E-liquid Flavor 1 · Other: E-liquid Flavor 2 · Other: E-liquid Flavor 3
E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
Appeal
Change in appeal at each flavor as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked) to 100 (most liked), with 'neither liked nor disliked' as midpoint.
Time frame: immediately after intervention (up to 15 minutes)
Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS)
Change in sweetness at each flavor as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).
Time frame: immediately after intervention (up to 15 minutes)
Reinforcing Efficacy of Multiple Choice Procedure
Change in reinforcing value at each flavor via the Multiple Choice Procedure. Participants will use the Multiple Choice Procedure to self-report their responses using a computer mouse to indicate where across a series of options their answer falls. Following each puffing bout, participants will be asked to make discrete hypothetical choices between 10-puffs of the e-cig they had just used or a series of 10 monetary values ranging from $0.01 to $5.12. The minimum monetary value at which money is chosen over the e-cig puffs is a contingency-based estimate of e-cig value.
Time frame: immediately after intervention (up to 15 minutes)
| Milestone | Condition 1: Strawberry, Then Menthol, Then Unflavored | Condition 2: Strawberry, Unflavored, Menthol | Condition 3: Menthol, Strawberry, Unflavored | Condition 4: Menthol, Unflavored, Strawberry | Condition 5: Unflavored, Strawberry, Menthol | Condition 6: Unflavored, Menthol, Strawberry |
|---|---|---|---|---|---|---|
| Started | 10 | 11 | 11 | 10 | 11 | 13 |
| Completed lab 1 | 10 | 10 | 11 | 10 | 9 | 12 |
| Completed lab 2 | 10 | 10 | 11 | 10 | 9 | 12 |
| Completed lab 3 | 10 | 10 | 11 | 10 | 9 | 12 |
| Completed | 10 | 10 | 10 | 10 | 9 | 12 |
| Not completed | 0 | 1 | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 0 |
Change in appeal at each flavor as measured by the computerized Labeled Hedonic Scale (LHS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Labeled Hedonic Scale (LHS) is a bipolar category ratio scale that ranges from -100 (most disliked) to 100 (most liked), with 'neither liked nor disliked' as midpoint.
| units on a scale | Males - Strawberry Flavor | Males - Menthol Flavor | Males - Unflavored | Females - Strawberry Flavor | Females - Menthol Flavor | Females - Unflavored |
|---|---|---|---|---|---|---|
| Appeal | 18.20 ± 5.27 | 14.93 ± 7.04 | -5.98 ± 7.30 | 13.99 ± 7.52 | 7.88 ± 7.76 | -5.12 ± 6.25 |
Change in sweetness at each flavor as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).
| sweetness score on the gLMS scale | Males - Strawberry Flavor | Males - Menthol Flavor | Males - Unflavored | Females - Strawberry Flavor | Females - Menthol Flavor | Females - Unflavored |
|---|---|---|---|---|---|---|
| Sensory Effects Assessed Using the Computerized Generalized Labeled Magnitude Scale (gLMS) | 24.73 ± 3.39 | 17.61 ± 3.09 | 10.84 ± 2.64 | 20.62 ± 3.66 | 11.59 ± 2.39 | 7.90 ± 1.98 |
Change in reinforcing value at each flavor via the Multiple Choice Procedure. Participants will use the Multiple Choice Procedure to self-report their responses using a computer mouse to indicate where across a series of options their answer falls. Following each puffing bout, participants will be asked to make discrete hypothetical choices between 10-puffs of the e-cig they had just used or a series of 10 monetary values ranging from $0.01 to $5.12. The minimum monetary value at which money is chosen over the e-cig puffs is a contingency-based estimate of e-cig value.
| dollars | Males - Strawberry Flavor | Males - Menthol Flavor | Males - Unflavored | Females - Strawberry Flavor | Females - Menthol Flavor | Females - Unflavored |
|---|---|---|---|---|---|---|
| Reinforcing Efficacy of Multiple Choice Procedure | 2.59 ± 0.51 | 2.82 ± 0.61 | 1.98 ± 0.53 | 2.85 ± 0.61 | 1.99 ± 0.45 | 2.38 ± 0.43 |
Collected over Adverse events were collected beginning at Lab 1 through Lab 4, including any Adverse events that occur between visits. This time period varies by participants but is approximately 1 week to 1 month.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Strawberry Flavor | 0/66 (0%) | 1/66 (1.5%) | 2/66 (3%) |
| Menthol Flavor | 0/66 (0%) | 1/66 (1.5%) | 1/66 (1.5%) |
| Unflavored | 0/66 (0%) | 0/66 (0%) | 0/66 (0%) |
| Event | Strawberry Flavor | Menthol Flavor | Unflavored |
|---|---|---|---|
| Kidney Stones with an emergency room visitRenal and urinary disorders | 1/66 | 0/66 | 0/66 |
| Anaphylactic Reaction to ShellfishGeneral disorders | 0/66 | 1/66 | 0/66 |
| Event | Strawberry Flavor | Menthol Flavor | Unflavored |
|---|---|---|---|
| High Blood PressureVascular disorders | 1/66 | 0/66 | — |
| HeadacheNervous system disorders | 1/66 | 0/66 | — |
| Abdominal PainInjury, poisoning and procedural complications | 1/66 | 0/66 | — |
| Chest PainInjury, poisoning and procedural complications | 1/66 | 0/66 | — |
| Difficulty SleepingInjury, poisoning and procedural complications | 1/66 | 0/66 | — |
| NauseaGastrointestinal disorders | 0/66 | 1/66 | — |
| Age, Categorical(Participants) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 66 |
| >=65 years | 0 |
| Age, Continuous(years) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| Mean | 34.83 ± 6.89 |
| Sex: Female, Male(Participants) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| Female | 35 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| Hispanic or Latino | 15 |
| Not Hispanic or Latino | 51 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 20 |
| White | 31 |
| More than one race | 0 |
| Unknown or Not Reported | 7 |
| Region of Enrollment(participants) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| United States | 66 |
| Cigarettes Smoked Per Day(cigarettes per day) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| Mean | 6.78 ± 4.39 |
| Intake Carbon Monoxide Level(parts per million) | Three Lab Sessions in Which a Single Flavor/Lab Session is Administered |
|---|---|
| Mean | 17.76 ± 13.19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2024 to primary completion in Jul 2025, 14 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's 14 months is below that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.